Insights7 min read
FDA already treats plant cameras as a quality system
Across published India Form 483s, FDA cites firms not for lacking CCTV — but for footage that wasn’t recorded, got purged, had blind spots, or nobody was watching.
If you run a drug plant with cameras over the fill line, you already know the uncomfortable truth: having CCTV is not the same as having a quality system. FDA’s published Form 483s for India facilities make that explicit.
We reviewed all 192 published India 483 PDFs available from the FDA Data Dashboard (as of July 2026). Of the 104 with extractable text, 25 mention video, camera, CCTV, or footage. Eight of those — across five firms — are about continuous floor monitoring failing as a GMP control. Every one of those eight drew OAI or VAI.
The pattern: cameras present, discipline missing
FDA is not writing these firms up for lacking cameras. They are writing them up for the gaps that turn cameras into theater:
- Footage never recorded, even with DVR and monitors installed
- Footage used in investigations automatically purged
- Blind spots — too close, too far, blocked, or critical setup out of view
- A human assigned to watch the live feed who left the monitor
That last failure mode is the clearest product signal in the corpus: continuous watching by a person does not survive a shift.
Eight 483s where continuous CCTV failed
| Firm | Site | Date | Class | What FDA found |
|---|---|---|---|---|
| Zydus Lifesciences | Moraiya | May 2019 | OAI | CCTV + DVR + monitors over fill lines, but QA did not record production / aseptic media fills; one camera obstructed |
| Cipla | Goa | Sep 2019 | OAI | Camera too close / too far / view blocked; firm did not use CGMP CCTV to observe aseptic filling |
| Biocon Biologics | Bengaluru | Aug 2022 | VAI | CCTV used for OOS investigations was auto-purged; no save process; software never validated |
| Kilitch Healthcare | Navi Mumbai | Oct 2023 | OAI | FDA reviewed CCTV: barefoot / ungowned work in Grade C; EM samples recorded as collected that never were |
| Eugia Pharma | Sangareddy | Feb 2024 | OAI | Operators supposed to watch CCTV continuously admitted leaving for weight checks / bathroom; per-batch review removed by change control |
| Eugia Pharma | Sangareddy | Feb 2026 | OAI | Poor aseptic practice and glove monitoring seen on CCTV review; critical setup not visible via windows or cameras |
Two Eugia observations appear because they are separate inspections at the same Sangareddy facility — camera-review gaps can recur years apart. See also how OAI escalates to Warning Letters.
Seventeen more: smoke-study video
The other camera mentions are mostly airflow-visualization (smoke study) critiques — insufficient smoke, zoomed angles that hide the RABS, edited footage, or QA sign-off on video that already shows turbulence. Those are one-off validation recordings, not continuous floor monitoring. They still matter: video evidence is already how FDA adjudicates aseptic compliance in India.
What this means for the floor
The compliance expectation is no longer “do you have cameras?” It is whether the system actually records, retains, covers the critical path, and reviews without depending on someone staring at a monitor for an entire batch.
FDA cited Eugia because an operator walked away from the CCTV monitor for a bathroom break. A coworker that never stops watching — and keeps every second searchable — is the structural answer to that finding.
Sources & method
- FDA Data Dashboard — published India Form 483 PDFs (192 documents; 104 text-extractable)
- Narrative search for video / camera / CCTV / footage in extractable text
- Classifications (OAI / VAI) from associated inspection outcomes in dashboard exports
- Analysis dated July 2026; FY figures use FDA fiscal years (Oct–Sep)
On the open web
You do not need our extract to see the pattern. FDA’s CDER reading-room file for Eugia (Feb 2026) states that poor aseptic practices and inadequate glove monitoring were observed on CCTV review — and that CCTV is the primary method for QA to review filling when windows cannot cover critical interventions. Pharma microbiology write-ups of the Kilitch 483 likewise quote investigators reviewing CCTV that showed ungowned / barefoot work in Grade C.